Nonprofit · EIN 59-1361955
DIABETES RESEARCH INSTITUTE FOUNDATION INC
Tax-exempt · MIAMI, FL 33136
Financials
| Year ended | Form | Revenue | Expenses | Net income | Total assets | Liabilities | Net assets |
|---|---|---|---|---|---|---|---|
| June 30, 2025 | 990 | $11,393,437 | $13,113,198 | -$1,719,761 | $26,581,774 | $1,971,011 | $24,610,763 |
| June 30, 2024 | 990 | $9,491,932 | $14,123,317 | -$4,631,385 | $26,391,689 | $1,746,872 | $24,644,817 |
| June 30, 2023 | 990 | $7,129,662 | $11,554,214 | -$4,424,552 | $28,164,828 | $799,974 | $27,364,854 |
Financial details: 990 for the year ended June 30, 2025
Revenue
- Contributions, gifts and grants
- $10,601,774
- Program service revenue
- $0
- Investment income
- $788,338
- Net gain from sales of assets
- $61,428
- Other revenue
- $3,325
Expenses
- Grants and similar amounts paid
- $7,081,720
- Compensation of officers, directors and key employees
- $595,702
- Other salaries and wages
- $1,795,990
- Salaries, compensation and benefits (total)
- $2,852,307
- Professional fundraising fees
- $369,182
- Legal fees
- $30,126
- Accounting fees
- $74,524
- Occupancy
- $301,114
- Travel
- $78,656
- Depreciation
- $39,996
- Program services (functional)
- $8,404,486
- Management and general (functional)
- $1,810,163
- Fundraising (functional)
- $2,898,549
Balance sheet and other
- Total assets, start of year
- $26,391,689
- Total assets, end of year
- $26,581,774
- Total liabilities, end of year
- $1,971,011
- Net assets, end of year
- $24,610,763
- Land, buildings and equipment
- $74,777
- Publicly traded securities
- $21,271,692
- Net assets without donor restrictions
- $2,373,230
- Net assets with donor restrictions
- $22,237,533
- Gross receipts
- $18,188,764
- Employees
- 17
- Volunteers
- 200
- Year formed
- 1974
- State of legal domicile
- FL
From the e-filed returns the IRS publishes as XML (latest three processing years; amended returns replace the original). PDF copies at the IRS.
Officers, directors and key employees
As listed on the 990 for the year ended June 30, 2025, highest compensation first.
| Name | Title | Hours / week | Compensation | Other / benefits |
|---|---|---|---|---|
| MICHAEL BURTON | CHIEF EXECUTIVE OFFICER Officer | 50 | $370,500 | $34,014 |
| MICHAEL MYERS | CHIEF COMMUNICATIONS OFFICER Highest-paid employee | 50 | $225,000 | $33,071 |
| AMY POWERS | CHIEF DEVELOPMENT OFFICER Key employee | 50 | $225,202 | $25,888 |
| JILL SHAPIRO-MILLER | EXECUTIVE VICE PRESIDENT Highest-paid employee | 50 | $198,550 | $16,336 |
| JESSICA SINNES | CHIEF OPERATING OFFICER Highest-paid employee | 50 | $190,260 | $12,115 |
| JOANN FLICK | DIRECTOR OF MAJOR GIFTS Highest-paid employee | 50 | $159,538 | $18,966 |
| THOMAS KARLYA | EXECUTIVE VICE PRESIDENT Highest-paid employee | 50 | $147,142 | $18,966 |
| BONNIE INSERRA | MEMBER AT LARGE Trustee or director, Officer | 5 | $0 | $0 |
| BRUCE SIEGEL | TREASURER Trustee or director, Officer | 5 | $0 | $0 |
| CHARLES RIZZO | AT LARGE Trustee or director, Officer | 5 | $0 | $0 |
| HAROLD DORAN JR | IMMEDIATE PAST BOARD CHAIRMAN Trustee or director, Officer | 5 | $0 | $0 |
| JOHN DOSCAS | VICE CHAIRMAN Trustee or director, Officer | 5 | $0 | $0 |
| MARC S GOODMAN | AT LARGE Trustee or director, Officer | 5 | $0 | $0 |
| MATTHEW STUBBS | SECRETARY Trustee or director, Officer | 5 | $0 | $0 |
| WILLIAM FISHLINGER | BOARD CHAIRMAN Trustee or director, Officer | 5 | $0 | $0 |
14 more people on this return
| Name | Title | Hours / week | Compensation |
|---|---|---|---|
| BRUCE WALLER | DIRECTOR Trustee or director | 1 | $0 |
| ELEANOR KOSOW | DIRECTOR Trustee or director | 1 | $0 |
| ESTHER GOODMAN | DIRECTOR Trustee or director | 1 | $0 |
| JOHN CARRION | DIRECTOR Trustee or director | 1 | $0 |
| LINDSEY INSERRA-HUGHES | DIRECTOR Trustee or director | 1 | $0 |
| MARC GOLDFARB | DIRECTOR Trustee or director | 1 | $0 |
| MARLENE BERG | DIRECTOR Trustee or director | 1 | $0 |
| RAMON POO | DIRECTOR Trustee or director | 1 | $0 |
| RICHARD TONKINSON | DIRECTOR Trustee or director | 1 | $0 |
| ROGER SILVERSTEIN | DIRECTOR Trustee or director | 1 | $0 |
| RONALD DARLING | DIRECTOR Trustee or director | 1 | $0 |
| SCARLETT LEUNG | DIRECTOR Trustee or director | 1 | $0 |
| SEAN MCGARVEY | DIRECTOR Trustee or director | 1 | $0 |
| STEPHEN RIZZO | DIRECTOR Trustee or director | 1 | $0 |
990 for the year ended June 30, 2024: 31 people
| Name | Title | Hours / week | Compensation | Other / benefits |
|---|---|---|---|---|
| MICHAEL BURTON | CHIEF EXECUTIVE OFFICER (AS OF 07/2023) Officer | 50 | $318,750 | $29,680 |
| SAMANTHA DAVIS | CHIEF FINANCIAL OFFICER Officer | 60 | $160,000 | $83,295 |
| AMY POWERS | CHIEF DEVELOPMENT OFFICER Key employee | 50 | $210,000 | $23,461 |
| THOMAS KARLYA | EXECUTIVE VICE PRESIDENT Highest-paid employee | 50 | $207,000 | $17,071 |
| JILL SHAPIRO-MILLER | EXECUTIVE VICE PRESIDENT Highest-paid employee | 50 | $198,550 | $11,913 |
| MICHAEL MYERS | CHIEF COMMUNICATIONS OFFICER Highest-paid employee | 50 | $147,115 | $13,734 |
| JOANN FLICK | DIRECTOR OF MAJOR GIFTS Highest-paid employee | 50 | $135,960 | $22,380 |
| JESSICA SINNES | ASSISTANT VP, PHILANTHROPY Highest-paid employee | 50 | $127,000 | $7,620 |
| BONNIE INSERRA | MEMBER AT LARGE Trustee or director, Officer | 5 | $0 | $0 |
| BRUCE SIEGEL | TREASURER Trustee or director, Officer | 5 | $0 | $0 |
| CHARLES RIZZO | AT LARGE Trustee or director, Officer | 5 | $0 | $0 |
| HAROLD DORAN JR | IMMEDIATE PAST BOARD CHAIRMAN Trustee or director, Officer | 5 | $0 | $0 |
| JOHN DOSCAS | VICE CHAIRMAN Trustee or director, Officer | 5 | $0 | $0 |
| MARC S GOODMAN | AT LARGE Trustee or director, Officer | 5 | $0 | $0 |
| MATTHEW STUBBS | SECRETARY Trustee or director, Officer | 5 | $0 | $0 |
| WILLIAM FISHLINGER | BOARD CHAIRMAN Trustee or director, Officer | 5 | $0 | $0 |
| BRUCE WALLER | DIRECTOR Trustee or director | 1 | $0 | $0 |
| ELEANOR KOSOW | DIRECTOR Trustee or director | 1 | $0 | $0 |
| ESTHER GOODMAN | DIRECTOR Trustee or director | 1 | $0 | $0 |
| JILL VINER | DIRECTOR Trustee or director | 1 | $0 | $0 |
| LINDSEY INSERRA-HUGHES | DIRECTOR Trustee or director | 1 | $0 | $0 |
| MARC GOLDFARB | DIRECTOR Trustee or director | 1 | $0 | $0 |
| MARLENE BERG | DIRECTOR Trustee or director | 1 | $0 | $0 |
| RAMON POO | DIRECTOR Trustee or director | 1 | $0 | $0 |
| RICARDO SALMON | DIRECTOR Trustee or director | 1 | $0 | $0 |
| RICHARD TONKINSON | DIRECTOR Trustee or director | 1 | $0 | $0 |
| ROGER SILVERSTEIN | DIRECTOR (AS OF 07/2023) Trustee or director | 1 | $0 | $0 |
| RONALD DARLING | DIRECTOR Trustee or director | 1 | $0 | $0 |
| SCARLETT LEUNG | DIRECTOR Trustee or director | 1 | $0 | $0 |
| SEAN MCGARVEY | DIRECTOR Trustee or director | 1 | $0 | $0 |
| STEPHEN RIZZO | DIRECTOR Trustee or director | 1 | $0 | $0 |
990 for the year ended June 30, 2023: 30 people
| Name | Title | Hours / week | Compensation | Other / benefits |
|---|---|---|---|---|
| SEAN KRAMER | CHIEF EXECUTIVE OFFICER Officer | 50 | $237,501 | $14,141 |
| AMY POWERS | CHIEF DEVELOPMENT OFFICER Key employee | 50 | $208,322 | $27,000 |
| JILL SHAPIRO-MILLER | EXECUTIVE VICE PRESIDENT Highest-paid employee | 50 | $197,952 | $27,000 |
| THOMAS KARLYA | EXECUTIVE VICE PRESIDENT Highest-paid employee | 50 | $197,952 | $12,420 |
| SAMANTHA DAVIS | CHIEF FINANCIAL OFFICER Officer | 60 | $142,759 | $8,711 |
| JESSICA SINNES | ASSISTANT VP, PHILANTHROPY Highest-paid employee | 50 | $122,890 | $17,205 |
| STEPHANIE LANZA | DIRECTOR STRATEGIC PARTNERSHIP Highest-paid employee | 50 | $122,228 | $12,505 |
| MACKENZIE CRANE | DIRECTOR OF MAJOR GIFTS Highest-paid employee | 50 | $116,822 | $7,050 |
| WILLIAM FISHLINGER | BOARD CHAIRMAN Trustee or director, Officer | 5 | $0 | $0 |
| JOHN DOSCAS | VICE CHAIRMAN Trustee or director, Officer | 5 | $0 | $0 |
| HAROLD DORAN JR | IMMEDIATE PAST BOARD CHAIRMAN Trustee or director, Officer | 5 | $0 | $0 |
| BRUCE SIEGEL | TREASURER Trustee or director, Officer | 5 | $0 | $0 |
| MATTHEW STUBBS | SECRETARY Trustee or director, Officer | 5 | $0 | $0 |
| MARC S GOODMAN | AT LARGE Trustee or director, Officer | 5 | $0 | $0 |
| CHARLES RIZZO | AT LARGE Trustee or director, Officer | 5 | $0 | $0 |
| MARLENE BERG | DIRECTOR Trustee or director | 1 | $0 | $0 |
| RONALD DARLING | DIRECTOR Trustee or director | 1 | $0 | $0 |
| MARC GOLDFARB | DIRECTOR Trustee or director | 1 | $0 | $0 |
| ESTHER GOODMAN | DIRECTOR Trustee or director | 1 | $0 | $0 |
| BONNIE INSERRA | DIRECTOR Trustee or director | 1 | $0 | $0 |
| LINDSEY INSERRA-HUGHES | DIRECTOR Trustee or director | 1 | $0 | $0 |
| ELEANOR KOSOW | DIRECTOR Trustee or director | 1 | $0 | $0 |
| SCARLETT LEUNG | DIRECTOR Trustee or director | 1 | $0 | $0 |
| RAMON POO | DIRECTOR Trustee or director | 1 | $0 | $0 |
| STEPHEN RIZZO | DIRECTOR Trustee or director | 1 | $0 | $0 |
| RICARDO SALMON | DIRECTOR Trustee or director | 1 | $0 | $0 |
| SAM TALBOT | DIRECTOR Trustee or director | 1 | $0 | $0 |
| RICHARD TONKINSON | DIRECTOR Trustee or director | 1 | $0 | $0 |
| JILL VINER | DIRECTOR Trustee or director | 1 | $0 | $0 |
| BRUCE WALLER | DIRECTOR Trustee or director | 1 | $0 | $0 |
Address and contacts
- Address (IRS master file)
- 1450 NW 10TH AVE, MIAMI, FL 33136-1011
- In care of
- % SAMANTHA DAVIS
- Principal officer (990 for 2024)
- MICHAEL BURTON, 1450 NW 10TH AVENUE 2ND FLOOR, MIAMI, FL 33136
- Signed the 990
- SAMANTHA DAVIS, CFO
- Phone
- (954) 964-4040
- Website
- WWW.DIABETESRESEARCH.ORG
- Return prepared by
- BDO USA
Mission
TO PROVIDE THE DIABETES RESEARCH INSTITUTE WITH THE FUNDING TO CURE DIABETES NOW.
Program accomplishments
- THE DIABETES RESEARCH INSTITUTE FOUNDATION FUNDS BASIC, PRE-CLINICAL AND PATIENT-BASED RESEARCH STUDIES, INCLUDING CLINICAL STUDIES, SEVERAL OF WHICH ARE SIMULTANEOUSLY UNDERWAY AT THE DIABETES RESEARCH INSTITUTE (DRI) AND OTHER COLLABORATING RESEARCH FACILITIES. SUPPORT FROM THE DIABETES RESEARCH INSTITUTE FOUNDATION HAS ENABLED THE INTRODUCTION OF AFFINITY GROUPS AT THE DRI, A NEW STRATEGIC TOOL TO ACCELERATE THE FUTURE OF TYPE 1 DIABETES RESEARCH. THESE GROUPS ARE DESIGNED TO FOSTER COLLABORATION, ENCOURAGE INNOVATIVE THINKING AND STREAMLINE PROBLEM-SOLVING. THROUGH THESE NEW AFFINITY GROUPS, EXPERTS AND SPECIALISTS ACROSS DISCIPLINES, INCLUDING SURGEONS, ENGINEERS, IMMUNOLOGISTS, CHEMISTS AND ENDOCRINOLOGISTS, COME TOGETHER TO FOCUS ON THREE CRITICAL AREAS: IMMUNOLOGY/IMMUNE MODULATION, DEVICES TO SUPPORT ISLET TRANSPLANTATION AND INSULIN-PRODUCING BETA CELL ROBUSTNESS AND AUGMENTATION. IN THE AREA OF IMMUNOLOGY, DRIF HAS FUNDED DRI RESEARCH PROJECTS THAT FOCUS ON ESTABLISHING IMMUNE TOLERANCE AND REVERSING AUTOIMMUNITY, THE BODY'S DESTRUCTION OF THE INSULIN-PRODUCING CELLS WHICH CAUSES THE ONSET OF THE DISEASE. ONE SUCH STUDY INVOLVES THE MONOCLONAL ANTIBODY AT-1501 WHICH WAS TESTED IN PRECLINICAL MODELS, LEADING TO LONG-TERM GRAFT SURVIVAL IN BOTH ISLET AND KIDNEY TRANSPLANTS, CONFIRMING ITS IMMUNOSUPPRESSIVE POTENTIAL. ANOTHER EXCITING STUDY INVOLVES THE USE OF "LIPONANO CLUSTERS" WHICH PROVIDE CONTINUOUS DELIVERY OF ANTI-INFLAMMATORY COMPOUNDS TO TRANSPLANTED INSULIN-PRODUCING CELLS, REDUCING INFLAMMATION AND PROTECTING THESE CELLS FROM BEING ATTACKED BY THE IMMUNE SYSTEM. IN THE AREA OF DEVICES, DRIF-FUNDED RESEARCHERS ARE FOCUSED ON REFINING STRATEGIES FOR HIDING AND PROTECTING INSULIN-PRODUCING CELLS FROM THE ATTACK BY THE IMMUNE SYSTEM WITH THE USE OF ENCAPSULATION AND HOUSING DEVICES FOR CELLS. DRI RESEARCHERS ARE ADVANCING CONFORMAL COATING TECHNOLOGY COMBINED WITH THE CELL POUCH SYSTEM TO PROTECT ISLET CELLS. DRI RESEARCHERS ARE ALSO WORKING TO DEVELOP THE IMMUNOSUPPRESSION-FREE VASCULARIZED DEVICE FOR ISLET TRANSPLANTATION (VADIT), AN INNOVATIVE APPROACH THAT INTEGRATES A VASCULARIZED DEVICE WITH A TISSUE-BASED DRUG DELIVERY SYSTEM TO ENABLE ISLET TRANSPLANTATION WITHOUT THE NEED FOR LIFELONG IMMUNOSUPPRESSION. ADDITIONALLY, DRI SCIENTISTS ARE STUDYING PATENTED FASL TECHNOLOGY, COMBINING A SYNTHETIC FORM OF THE PROTEIN FASL WITH A SPECIAL MICROGEL TO SAFELY PROTECT TRANSPLANTED ISLETS AND INDUCE LOCAL IMMUNE TOLERANCE. ANOTHER MAJOR RESEARCH AREA THAT DRIF SUPPORTS IS THE DEVELOPMENT OF AN UNLIMITED SUPPLY OF INSULIN-PRODUCING CELLS. DRIF-FUNDED STUDIES HAVE LED TO SIGNIFICANT PROGRESS IN STIMULATING THE REGENERATION OF PANCREATIC STEM CELLS INTO INSULIN-PRODUCING CELLS USING A SINGLE FDA-APPROVED MOLECULE, BMP-7. THIS SIGNIFICANT FINDING OPENS THE DOOR TO A NATURAL CELL SUPPLY BANK WITHIN THE PATIENT'S BODY, ADDRESSING SEVERAL ONGOING CHALLENGES FOR CURING THE DISEASE. THE DRIF HAS FUNDED INTERNATIONAL RESEARCHER TRAINING AND KEY COLLABORATIVE PROGRAMS THAT HELP ACCELERATE RESEARCH PROGRESS THROUGH THE SHARING OF IDEAS AND ADVANCEMENTS. DRIF ALSO HOSTS AND PARTICIPATES IN A VARIETY OF INFORMATIONAL WORKSHOPS FOR PEOPLE WITH DIABETES AND THEIR FAMILIES FOCUSING ON THE LATEST ADVANCES TOWARD A CURE AND THE NEWEST DIABETES MANAGEMENT TECHNIQUES. THROUGH ITS WEBSITE DIABETESRESEARCH.ORG, THE DRIF PROVIDES 'NEWS YOU CAN USE RESEARCH UPDATES FOR THOSE LIVING WITH DIABETES AND THEIR FAMILY MEMBERS IN THE FORM OF E-NEWSLETTERS, VIDEOS, EMAIL ANNOUNCEMENTS AND INFORMATION VIA SOCIAL MEDIA.Expenses $7,081,720 · grants $7,081,720
- COMMUNITY DIABETES EDUCATION. THE DIABETES RESEARCH INSTITUTE FOUNDATION PROVIDES INFORMATION TO THE PUBLIC VIA ITS WEBSITE, LITERATURE, SPEAKERS, CONFERENCES, PRINT INTERVIEWS AND TOLL FREE NUMBER 800-321-3437. THE PUBLIC GAINS KNOWLEDGE ABOUT DIABETES, DIABETES CARE, NUTRITION AND RESEARCH TOWARD FINDING A CURE FOR DIABETES.Expenses $1,322,766
What it must file and when
IRS records say it files Form 990 or 990-EZ. Based on its last return; a smaller organization may file the 990-N. Its accounting year ends in June, so each return is due on the 15th day of the 5th month after that.
| Tax year | Year ended | Due | IRS public records |
|---|---|---|---|
| 2025 | June 30, 2026 | November 16, 2026 | Not due yet |
| 2024 | June 30, 2025 | November 17, 2025 | 990 on file |
| 2023 | June 30, 2024 | November 15, 2024 | 990 on file |
IRS record
- EIN
- 59-1361955
- Tax-exempt status
- 501(c)(3): Charitable, religious, educational or scientific organization
- Foundation status
- Publicly supported organization (170(b)(1)(A)(vi))
- Donations deductible (Pub 78)
- Public charity, 50% deduction limit
- Exempt since
- 1973
- Accounting year ends
- June
- Files
- Form 990 or 990-EZ
- Category (NTEE)
- Medical research (H85I)
- Assets (IRS master file)
- $26,581,774
- Income (IRS master file)
- $18,188,764
Filing history
| Form | Year ended | Revenue | Expenses | Assets | Return |
|---|---|---|---|---|---|
| 990 | June 2025 | $11,393,437 | $13,113,198 | $26,581,774 | IRS |
| 990 | June 2024 | $9,491,932 | $14,123,317 | $26,391,689 | IRS |
| 990 | June 2023 | $7,129,662 | $11,554,214 | $28,164,828 | XML |
| 990 | June 2022 | $11,474,074 | $11,938,552 | $32,244,637 | IRS |
| 990 | June 2021 | – | – | – | IRS |
| 990 | June 2020 | – | – | – | IRS |
| 990 | June 2019 | – | – | – | IRS |
| 990 | June 2018 | – | – | – | IRS |
990-N: the IRS bulk file holds only the latest e-Postcard per organization; earlier years come from archived copies of that file since 2020 and can have gaps (the IRS e-Postcard search lists every one). 990, 990-EZ, 990-PF, 990-T: every e-filed return in the IRS e-file index since 2019; XML for the latest three processing years, amounts from the IRS Statistics of Income extracts before that. PDF copies and determination letters at the IRS (search EIN 59-1361955).
Questions about DIABETES RESEARCH INSTITUTE FOUNDATION INC
- What is the EIN of DIABETES RESEARCH INSTITUTE FOUNDATION INC?
- The employer identification number (EIN) of DIABETES RESEARCH INSTITUTE FOUNDATION INC is 59-1361955.
- Is DIABETES RESEARCH INSTITUTE FOUNDATION INC tax-exempt?
- Yes. The IRS lists it as tax-exempt under section 501(c)(3) since 1973.
- Are donations to DIABETES RESEARCH INSTITUTE FOUNDATION INC tax-deductible?
- Yes. It is listed in IRS Publication 78 (Public charity, 50% deduction limit).
- Which annual return does DIABETES RESEARCH INSTITUTE FOUNDATION INC file?
- Form 990 or 990-EZ. Based on its last return; a smaller organization may file the 990-N.
- When is the next return of DIABETES RESEARCH INSTITUTE FOUNDATION INC due?
- The return for tax year 2025 (the year ending June 30, 2026) is due November 16, 2026. Form 8868 extends it by six months; the 990-N cannot be extended.
- When did DIABETES RESEARCH INSTITUTE FOUNDATION INC last file with the IRS?
- The latest return in the IRS public files is the 990 for the year ended June 2025.
- Who is the principal officer of DIABETES RESEARCH INSTITUTE FOUNDATION INC?
- The 990 for the year ended June 30, 2025 names MICHAEL BURTON.
- Who are the officers and directors of DIABETES RESEARCH INSTITUTE FOUNDATION INC?
- The 990 for the year ended June 30, 2025 lists 29 people; 7 received compensation from the organization, the highest $370,500 (MICHAEL BURTON, CHIEF EXECUTIVE OFFICER).
- How much revenue does DIABETES RESEARCH INSTITUTE FOUNDATION INC have?
- On its 990 for the year ended June 30, 2025 it reported revenue of $11,393,437, expenses of $13,113,198 and total assets of $26,581,774 at year end.
Other nonprofits in MIAMI
- OPHTHALMOLOGY RESEARCH FOUNDATION INC EIN 23-7081974 · last filed 990 for 2025
- FLORIDA HEART RESEARCH FOUNDATION INC EIN 51-0474502 · last filed 990 for 2025
- KIRK A AND DOROTHY P LANDON FOUNDATION EIN 23-7148133 · last filed 990-PF for 2025
- CANCER SOCIETY OF THE BAHAMAS FOUNDATION INC EIN 32-0466135 · last filed 990-EZ for 2025
- THE MARK AND JANICE GOLD FAMILY FOUNDATION INC EIN 85-4351428 · last filed 990-PF for 2025
- CHARLES M VALLEE FOUNDATION FOR LONG COVID RESEARCH EIN 88-2425647 · last filed 990-PF for 2024
- MIAMI CANCER RESEARCH CENTER INC EIN 81-4748176 · last filed 990 for 2025
- BEELIVER INC EIN 93-1379300 · last filed 990-EZ for 2024